| Literature DB >> 2842522 |
W Shiu1, N Leung, M Li, W T Leung, A K Li.
Abstract
An open phase II study of high-dose 4'epidoxorubicin (90 mg/m2) was conducted in 33 patients with inoperable hepatocellular carcinoma. Three out of the 33 (9%) patients showed tumour response. The treatment was relatively well tolerated with a moderate degree of haematological toxicity and alopecia, and a mild degree of nausea and vomiting. The overall median survival was 72 days with a prolongation in the patients who showed some response.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2842522
Source DB: PubMed Journal: Jpn J Clin Oncol ISSN： 0368-2811 Impact factor: 3.019